- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01053546
Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer
Effects of Early vs Late Onset of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer
RATIONALE: Swallowing exercise therapy may improve the quality of life of head and neck cancer patients undergoing chemotherapy or radiation therapy.
PURPOSE: This randomized phase III trial is studying early onset of swallowing exercise therapy to see how well it works compared to late onset of swallowing exercise therapy in treating patients with head and neck cancer undergoing chemotherapy or radiation therapy.
Studienübersicht
Status
Bedingungen
- Kopf-Hals-Krebs
- Stadium I Kehlkopfkrebs
- Kehlkopfkrebs im Stadium II
- Stage I Hypopharyngeal Cancer
- Stage I Oropharyngeal Cancer
- Stage II Hypopharyngeal Cancer
- Stage II Oropharyngeal Cancer
- Stage III Hypopharyngeal Cancer
- Stage III Laryngeal Cancer
- Stage III Oropharyngeal Cancer
- Stage IV Hypopharyngeal Cancer
- Stage IV Laryngeal Cancer
- Stage IV Oropharyngeal Cancer
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. To assess the difference between early and late onset swallowing exercises on swallowing quality of life in patients undergoing chemo/radiation therapy for head and neck cancer.
SECONDARY OBJECTIVE:
I. To assess the difference between early and late onset swallowing exercises on swallowing function in patients undergoing radiation therapy for head and neck cancer.
TERTIARY OBJECTIVE:
I. To assess the difference between early and late onset swallowing exercises on: individual domains of swallowing quality of life; Penetration Aspiration Scale (PAS) as assessed via FEES; diet level (Dysphagia Outcome and Severity Scale (DOSS) as assessed via FEES; feeding tube duration (days); Eating Assessment Tool (EAT); lingual strength as assessed via lingual manometry; and percent weight loss and percent weight recovery.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
Arm I (Early exercise group): Patients perform swallowing exercises comprising lingual press, head lift, breath hold, Masako swallow, high pitch e, effortful swallow, and neck stretch and massage for 2 weeks prior to beginning radiotherapy and again immediately after completion of radiotherapy.
Arm II (Late exercise group): Patients begin performing swallowing exercises as in arm I 1 month after completion of radiotherapy.
In both arms, swallowing exercises are performed twice daily, 6 days a week, for 12 months following completion of radiotherapy.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
North Carolina
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Wake Forest University Health Sciences
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion
- Written informed consent must be obtained from all participants prior to beginning therapy (participants should have the ability to understand be willing to sign a written informed consent document)
- Individuals with oropharyngeal, hypopharyngeal, or laryngeal cancer of Stages I-IV undergoing radiation and chemo therapies at Wake Forest Baptist Medical Center
- Participants will have surgically received no more than selective neck dissection and tumor biopsy (participants who have undergone primary tumor resection or radical neck dissection will not be eligible)
- Participants must have completed a minimum of third grade education in order to answer questions of the quality of life survey
- Participants must be willing to participate in the swallowing exercise program
Exclusion
- Medical history of cerebrovascular accident, Parkinson's disease, any type of dementia, myasthenia gravis, or amyotrophic lateral sclerosis
- Previous radiation treatment for head/neck cancer
- Swallowing problem of etiology other than current lesion
- Pregnant women are not anticipated in the patient population, but would be excluded from participation in the study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Arm I (Early exercise group)
Patients perform swallowing exercises comprising lingual press, head lift, breath hold, Masako swallow, high pitch e, effortful swallow, and neck stretch and massage for 2 weeks prior to beginning radiotherapy and again immediately after completion of radiotherapy.
|
Nebenstudium
Andere Namen:
Nebenstudium
The early exercise group will start study exercises approximately two weeks prior to the onset of XRT.
The late exercise group will start study exercises one month after the completion of XRT.
Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
|
Experimental: Arm II (Late exercise group)
Patients begin performing swallowing exercises as in arm I 1 month after completion of radiotherapy.
|
Nebenstudium
Andere Namen:
Nebenstudium
The early exercise group will start study exercises approximately two weeks prior to the onset of XRT.
The late exercise group will start study exercises one month after the completion of XRT.
Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
M.D. Anderson Dysphagia Inventory (MDADI) swallowing quality of life score
Zeitfenster: Baseline and at 1, 3, 6, and 12 months following completion of radiotherapy
|
Baseline and at 1, 3, 6, and 12 months following completion of radiotherapy
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Penetration Aspiration Scale (PAS) as assessed via FEES
Zeitfenster: Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Diet level (Dysphagia Outcome and Severity Scale (DOSS)) as assessed via FEES
Zeitfenster: Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Feeding tube duration (days)
Zeitfenster: Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Eating Assessment Tool (EAT) quality of life score
Zeitfenster: Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Lingual strength as assessed by lingual manometry
Zeitfenster: Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Percent weight loss
Zeitfenster: Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Percent weight recovery
Zeitfenster: Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Baseline and at 1, 3, and 6 months following completion of radiotherapy
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Susan Butler, Wake Forest University Health Sciences
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen der Atemwege
- Neubildungen
- Neubildungen nach Standort
- Neubildungen der Atemwege
- Rachenneoplasmen
- Otorhinolaryngologische Neubildungen
- Rachenkrankheiten
- Stomatognathe Erkrankungen
- Otorhinolaryngologische Erkrankungen
- Kehlkopferkrankungen
- Kopf-Hals-Neubildungen
- Oropharyngeale Neubildungen
- Larynxneoplasmen
- Hypopharyngeale Neubildungen
Andere Studien-ID-Nummern
- IRB00010437
- NCI-2009-01445 (Andere Kennung: CTRP)
- CCCWFU 98109 (Andere Kennung: Wake Forest University Health Sciences)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Bewertung der Lebensqualität
-
Memorial Sloan Kettering Cancer CenterAbgeschlossenAszitesVereinigte Staaten
-
Kutahya Health Sciences UniversityAbgeschlossenChronischer Schmerz | Juvenile idiopathische ArthritisTruthahn
-
Maastricht UniversityTNO; Netherlands Instititute for Health Services Research; University of TwenteAbgeschlossenHerzfehler | Diabetes mellitus, Typ 2 | Chronisch obstruktive Lungenerkrankung | AsthmaNiederlande
-
Avicenna Military HospitalAbgeschlossenPostoperative GenesungMarokko
-
Akdeniz UniversityAbgeschlossen
-
Memorial Sloan Kettering Cancer CenterBeendetDie Familien oder nächsten Angehörigen von Patienten, die am MSKCC wegen nichtkutaner Plattenepithelkarzinome behandelt wurden | Oberer AerodigestivtraktVereinigte Staaten
-
Buddhist Tzu Chi General HospitalAbgeschlossen
-
Hürriyet YılmazMedipol UniversityAbgeschlossenAdoleszente idiopathische Skoliose | Gesundheitsbezogene LebensqualitätTruthahn
-
Baskent UniversityAbgeschlossenParodontitis, Erwachsener
-
Wake Forest University Health SciencesRekrutierungNichtkleinzelliger Lungenkrebs Stadium III | Nicht resezierbares nicht-kleinzelliges LungenkarzinomVereinigte Staaten